Featured Research

from universities, journals, and other organizations

Registry for fatal lung disease aims to speed improvements in care

Date:
June 4, 2014
Source:
Duke Medicine
Summary:
A patient registry to help researchers and clinicians identify, manage and study people who have a progressive lung disease called idiopathic pulmonary fibrosis has been launched. The registry is the first multi-center registry in the United States focused specifically on idiopathic pulmonary fibrosis.

Duke Clinical Research Institute (DCRI) has launched a patient registry to help researchers and clinicians identify, manage and study people who have a progressive lung disease called idiopathic pulmonary fibrosis.

Related Articles


The registry, a joint effort by DCRI and Boehringer Ingelheim Pharmaceuticals, Inc., is the first multi-center registry in the United States focused specifically on idiopathic pulmonary fibrosis. It will include 300 adults recently diagnosed with the disease at 14 participating care sites throughout the country.

"Most of our knowledge about idiopathic pulmonary fibrosis comes from single-center studies and clinical trials, so there has been a tremendous need for a multi-center registry to help doctors, patients and advocates understand how this disease develops and progresses," said Scott Palmer, M.D., MHS, director of pulmonary research at DCRI.

Idiopathic pulmonary fibrosis affects as many as 132,000 people in the United States. It is a progressive, fatal disease characterized by scarring deep in the lung tissue that leads to respiratory or heart failure, pneumonia, and pulmonary embolism. The causes are unknown, although there may be genetic roots; there are no cures and no treatments approved by the Food and Drug Administration.

Palmer said the multi-site registry will help doctors who treat patients with idiopathic pulmonary fibrosis better understand how to diagnose and manage the disease, while it will also help researchers uncover the basic causes and mechanisms of the disease.

"Many factors, including limited understanding of IPF, have resulted in a poor outlook for most patients, with many patients living only three to five years after diagnosis," said Craig Conoscenti, M.D., Director and Idiopathic Pulmonary Fibrosis Program Lead, Clinical Development and Medical Affairs at Boehringer Ingelheim Pharmaceuticals, Inc.

"We are excited to be partnering with Duke Clinical Research Institute to bring important insights and new knowledge that we believe will provide a better understanding of how IPF both presents and progresses," Conoscenti said.

The registry will recruit patients over a two-year period from the 14 pulmonary care sites, providing a diverse geographic area and drawing upon leading scientific experts in the field. Patients will be followed for three to five years to provide time to better understand the factors associated with disease progression and natural history.

In addition, researchers will create a bio-repository that will include blood samples, including patient genetic material, to better understand the biomarkers or genetic factors impact on patient outcomes.


Story Source:

The above story is based on materials provided by Duke Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Duke Medicine. "Registry for fatal lung disease aims to speed improvements in care." ScienceDaily. ScienceDaily, 4 June 2014. <www.sciencedaily.com/releases/2014/06/140604105313.htm>.
Duke Medicine. (2014, June 4). Registry for fatal lung disease aims to speed improvements in care. ScienceDaily. Retrieved March 29, 2015 from www.sciencedaily.com/releases/2014/06/140604105313.htm
Duke Medicine. "Registry for fatal lung disease aims to speed improvements in care." ScienceDaily. www.sciencedaily.com/releases/2014/06/140604105313.htm (accessed March 29, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, March 29, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
WH Plan to Fight Antibiotic-Resistant Germs

WH Plan to Fight Antibiotic-Resistant Germs

AP (Mar. 27, 2015) The White House on Friday announced a five-year plan to fight the threat posed by antibiotic-resistant bacteria amid fears that once-treatable germs could become deadly. (March 27) Video provided by AP
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins